Enable Medicine–SEVERAL: investment, 202204 financing round Series A $60m led by Anthos Capital + General Catalyst

	Period	2022-04-07
	Money taker	Enable Medicine (US)
	Money source	SEVERAL
	Product	Enable BIOS platform (Biological Insight, Operating and Search)
	Product 2	venture capital

Enable Medicine. (4/7/22). "Press Release: Enable Medicine Raises $60M to Build the Search Engine For Biology". Menlo Park, CA.

Enable Medicine, a company that builds and integrates searchable maps of human disease, announces the closing of their Series A, raising $60M led by Anthos Capital and General Catalyst. Additional investors included Initialized Capital, Breyer Capital, Presight Capital, Axial, and founders or senior leaders of Recursion Pharmaceuticals, Roivant Sciences, and BridgeBio. With this round, the company is launching their spatial biology atlasing platform, empowering all biologists and clinicians to better understand how the organization of cells impact disease pathology, progression, and therapeutic response. Enable will use this fundraise to expand the product offerings it can provide to its research collaborators, including additional proteomic and transcriptomic assays, and increase the speed at which it generates searchable datasets and actionable insights from complex biological data.

Enable Medicine provides researchers with the ability to build comprehensive maps of disease biology. They do this through either indexing existing single-cell biological data, or generating novel spatial proteomic data in their lab in Menlo Park, California. Enable then systematically extracts scientific insights through an internally-developed biological operating system (BIOS): a fully cloud-based platform that gives researchers the ability to process, organize, index, query, and analyze high-parameter biological data. The power of the BIOS is fully appreciated when scientists can easily search across hundreds of patients’ worth of spatial maps, surfacing clinically important cell types, interactions, and neighborhoods that previously could not be identified without the data organized and optimized for querying.

To date, Enable Medicine has 50+ research collaborations ongoing on its platform, including work with labs at institutions including Harvard’s Dana-Farber Cancer Institute, Mayo Clinic, Parker Institute of Cancer Immunotherapy, Stanford University, UC San Francisco, and numerous others. Over the past year, Enable has generated more than one petabyte of data over 5,000+ clinically annotated patient samples. Enable is a co-author on recent research publications and pre-prints including in Ulcerative Colitis, Pancreatic Ductal Adenocarcinoma, and Non-Small Cell Lung Cancer, with a number of additional manuscripts across a variety of diseases currently being drafted and in review.

BIOS has also generated significant demand amongst biopharma companies, where clinicians and drug hunters use the platform to better understand patient segmentation strategies and mechanisms of action.The platform has begun to generate high-value therapeutic hypotheses, such as a greater understanding of certain cell types and interactions that could be driving non-response to therapies like Sanofi’s and Regeneron’s megablockbuster Dupixent, or Merck’s flagship cancer immunotherapy drug, Keytruda.

Enable is led by an interdisciplinary team of bioengineers, computational immunologists, and computer scientists and is supported by an advisory board of academic and industry leaders including Nobel Laureate Dr. Jim Allison and Dr. Padmanee Sharma (MD Anderson Cancer Center), Dr. Tom Bumol (Allen Institute of Immunology), Dr. Andrew Lo (MIT), Dr. James Zou (Stanford University), Dr. Christian Schuerch (University of Tubingen), Dr. Laurence Marton (AACR), and Dr. Paul Conley (10x Genomics, Twist Bioscience).

Sunil Bodapati
Leadership

Sunil is on the leadership team at Enable Medicine. He completed his undergraduate degree in Bioengineering from Stanford University before working at Palantir Technologies and Color Genomics as a product lead. He later joined, and then left, Stanford’s Bioengineering PhD program to build Enable Medicine. He spends his free time playing basketball.